



Attorney's Docket No. 5854-2 (44276/209251)

#7
Pat. Am. B.
10/1/01
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Kappes *et al.* Group Art Unit: 1648
Appl. No.: 09/719,340
Filed: April 13, 2001
For: CELL-BASED METHOD AND ASSAY FOR MEASURING THE
INFECTIVITY AND DRUG SENSITIVITY OF IMMUNODEFICIENCY
VIRUS

September 26, 2001

Commissioner for Patents
Washington, DC 20231

RECEIVED
OCT 05 2001
TECH CENTER 1600/2500

PRELIMINARY AMENDMENT

Dear Sir:

Please amend the above-identified application as follows:

In The Claims:

Please cancel claims 1-36 without prejudice or disclaimer.

Please add the following claims:

Sub.D2
B1
37. An immortalized cell characterized as expressing CCR5, CXCR4, and CD4 receptors and having stably incorporated a marker gene operably linked to a promoter, wherein expression of the marker gene occurs upon HIV infection of the cell.

38. The immortalized cell of claim 37, wherein said cell originates from HeLa.

Sub.C1
39. The immortalized cell of claim 37, wherein said marker gene encodes luciferase, β -galactosidase, green fluorescent protein, or a polypeptide that confers antibiotic resistance.

10/04/2001 HNDOR1 00000054 160605 09719340
01 FC:202 6.00 CH 120.00 OP